Refraktionsausgleich und Amblyopietherapie - Konservative Schielbehandlung im Kindesalter

Konservative Schielbehandlung umfasst sowohl die Behandlung von Kindern mit Amblyopie und/oder Strabismus als auch von Erwachsenen mit verschiedensten Binokularstörungen. Trotz der Unterschiede der einzelnen Krankheitsbilder, die hier in extenso darzustellen nicht möglich ist, fußt die konservative Therapie im Wesentlichen auf den 3 Säulen: Refraktionsausgleich, Amblyopietherapie und Prismentherapie. Unbestritten wichtig ist die Einhaltung der richtigen Reihenfolge der Therapiemaßnahmen. Am Anfang jeglicher orthoptischer Behandlung steht immer die korrekte Refraktionsbestimmung, wenn nötig in Zykloplegie und ggfs. der Ausgleich von Refraktionsfehlern. Erst dann folgt eventuell die Okklusionstherapie oder Verordnung von Prismen (auf deren Darstellung hier verzichtet wird). Der vorliegende Beitrag orientiert sich am Inhalt des AAD-Kurses „Konservative Schielbehandlung“ und stellt die Grundregeln der Brillenverordnung und Amblyopietherapie dar.

Literatur

• 1 Abrahamsson M, Fabian G, Sjöstrand J. Longitudinal changes in refraction and risk indicators for amblyopia.  Investig Ophthalmol Vis Sci. 1991;  Suppl
• 2 Abrahamsson M, Magnusson G, Sjöstrand J. Inheritance of strabismus and the gain of using heredity to determine populations risk of developing strabismus.  Acta Ophthalmolog Scand. 1999;  77 653-657
• 3 Abrahamsson M, Sjöstrand J. Astigmatic axis and amblyopia in childhood.  Acta Ophthalmol Scand. 2003;  81 33-37
• 4 Atkinson J, Braddick O, Wattam-Bell J, Durden K, Bobier W, Pointer J. Photorefractive screening of infants and effects of refractive correction.  Invest Ophthalmol Vis Sci. 1987;  Suppl ARVO abstracts 28 300
• 5 Atkinson J, Braddick O, Robier B, Anker S, Ehrlich D, King J, Watson P, Moore A. Two infant vision screening programmes: prediction and prevention of strabismus and amblyopia from photo- and videorefractive screening.  Eye. 1996;  10(Pt 2) 189-198
• 6 Atkinson J, Anker S, Bobier W, Braddick O, Durden K, Nardini M, Watson P. Normal emmetropization in infants with spectacle correction for hyperopia.  Invest Ophthalmol Vis Sci. 2000;  41 3726-3731
• 7 Attebo K, Ivers R Q, Mitchell P. Refractive errors in an older population: the Blue Mountains Eye Study.  Ophthalmology. 1999;  106 1066-1072
• 8 Awan M, Proudlock F A, Gottlob I. A randomized controlled trial of unilateral strabismic and mixed amblyopia using occlusion dose monitors to record compliance.  Invest Ophthalmol Vis Sci. 2005;  46 1435-1439
• 9 Barry J C, Loewen N. Experiences with cycloplegic drops in German-speaking centers of pediatric ophthalmology and stabology - results of a 1999 survey.  Klin Monatsbl Augenheilkd. 2001;  218 26-30
• 10 Cavazos H, Haase W. Ametropische Amblyopie.  ZPA. 1989;  10 217-222
• 11 Celebi S, Aykan U. The comparison of cyclopentolate and atropine in patients with refractive accommodative esotropia by means of retinoscopy, autorefractometry and biometric lens thickness.  Acta Ophthalmol Scand. 1999;  77 426-429
• 12 Cotter S A, Edwards A R, Arnold R W, Astle W F, Barnhardt C N, Beck R W. et al. . Treatment of strabismic amblyopia with refractive correction.  Am J Ophthalmol. 2007;  143 1060-1063
• 13 de Decker W. Persistierende Diplopie beim Begleitschielen.  Augenärztliche Fortbildung. 1982;  7 (Teil 3) 317
• 14 Egashira S M, Kish L L, Twelker J D, Mutti D O, Zadnik K, Adams A J. Comparison of cyclopentolate versus tropicamide cycloplegia in children.  Optom Vis Sci. 1993;  70 1019-1026
• 15 Fan D S, Rao S K, Ng J S, Yu C B, Lam D S. Comparative study on the safety and efficacy of different cycloplegic agents in children with darkly pigmented irides.  Clin Experiment Ophthalmol. 2004;  32 462-467
• 16 Fielder A R, Irwin M, Auld R, Cocker K D, Jones H S, Moseley M J. Compliance in amblyopia therapy: objective monitoring of occlusion.  Br J Ophthalmol. 1995;  79 585-589
• 17 Friedrich D, de Decker W. Iatrogene Diplopie durch Okklusion.  ZPA. 1987;  8 286-288
• 18 Fronius M, Cirina L, Cordey A, Ohrloff C. Visual improvement during psychophysical training in an adult amblyopic eye following visual loss in the contralateral eye.  Graefes Arch Clin Exp Ophthalmol. 2005;  243 278-280
• 19 Gusek-Schneider G C, Kulzer J, Boss A. How useful is the prescription of glasses in intermittent exotropia and decompensating exophoria?.  Klin Monatsbl Augenheilkd. 2006;  223 620-628
• 20 Haase W, Gräf M. Amblyopie. Kaufmann H (Hrsg). Strabismus. 3. Auflage. Stuttgart; Thieme 2004: 292-318
• 21 Haase W. Refraction in childhood as a risk factor for the development of amblyopia and/or strabismus. Recording a round table discussion at the 89th Congress of the German Society of Ophthalmology 25 September 1991 in Leipzig.  Klin Monatsbl Augenheilkd. 1994;  204 48-54
• 22 Haase W. Amblyopia. Part 2: Precautionary measures and therapy.  Ophthalmologe. 2003;  100 160-172
• 23 Halkiadakis I, Iliaki O, Kalyvianaki M I, Tsilimbaris M K. Occlusion therapy of unilateral amblyopia with botulinum toxin induced ptosis.  Semin Ophthalmol. 2007;  22 55-57
• 24 Hertle R W, Scheiman M M, Beck R W, Chandler D L, Bacal D A, Birch E. et al. . Stability of visual acuity improvement following discontinuation of amblyopia treatment in children aged 7 to 12 years.  Arch Ophthalmol. 2007;  125 655-659
• 25 Holmes J M, Edwards A R, Beck R W, Arnold R W, Johnson D A, Klimek D L. et al. . A randomized pilot study of near activities versus non-near activities during patching therapy for amblyopia.  J AAPOS. 2005;  9 129-136
• 26 Holmes J M, Kraker R T, Beck R W, Birch E E, Cotter S A, Everett D F. et al. . A randomized trial of prescribed patching regimens for treatment of severe amblyopia in children.  Ophthalmology. 2003;  110 2075-2087
• 27 Holmes J M, Beck R W, Kraker R T, Astle W F, Birch E E, Cole S R. et al. . Risk of amblyopia recurrence after cessation of treatment.  J AAPOS. 2004;  8 420-428
• 28 Holmes J M, Melia M, Bradfield Y S, Cruz O A, Forbes B. Pediatric Eye Disease Investigator Group . Factors associated with recurrence of amblyopia on cessation of patching.  Ophthalmology. 2007;  114 1427-1432
• 29 Ingram R M, Walker C, Wilson J M, Arnold P E, Dally S. Prediction of amblyopia and squint by means of refraction at age 1 year.  Br J Ophthalmol. 1986;  70 12-15
• 30 Kämpf U, Muchamedjarow F, Seiler T. Supportive amblyopia treatment by means of computer games with background stimulation; a placebo controlled pilot study of 10 days.  Klin Monatsbl Augenheilkd. 2001;  218 243-250
• 31 Klimek D L, Cruz O A, Scott W E, Davitt B V. Isoametropic amblyopia due to high hyperopia in children.  J AAPOS. 2004;  8 310-313
• 32 Lang J. Amblyopia and its treatment.  Ophthalmologe. 1997;  94 606-618
• 33 Leiba H, Shimshoni M, Oliver M, Gottesman N, Levartovsky S. Long-term follow-up of occlusion therapy in amblyopia.  Ophthalmology. 2001;  108 1552-1555
• 34 Leitlinie „Amblyopie“ von DOG und BVA. AWMF-Leitlinien-Register. Nr. 045/009. 
• 35 Lin L L, Shih Y F, Hsiao C H, Su T C, Chen C J, Hung P T. The cycloplegic effects of cyclopentolate and tropicamide on myopic children.  J Ocul Pharmacol Ther. 1998;  14 331-335
• 36 Loudon S E, Fronius M, Looman C W, Awan M, Simonsz B, van der Maas P J, Simonsz H J. Predictors and a remedy for noncompliance with amblyopia therapy in children measured with the occlusion dose monitor.  Invest Ophthalmol Vis Sci. 2006;  47 4393-4400
• 37 Manny R E, Hussein M, Scheiman M, Kurtz D, Niemann K, Zinzer K. COMET Study Group . Tropicamide (1 %): an effective cycloplegic agent for myopic children.  Invest Ophthalmol Vis Sci. 2001;  42 1728-1735
• 38 Mohan K, Saroha V, Sharma A. Successful occlusion therapy for amblyopia in 11- to 15-year-old children.  J Pediat Ophthalmol Strab. 2004;  41 89-95
• 39 Morrison D G, Palmer N J, Sinatra R B, Donahue S. Severe amblyopia of the sound eye resulting from atropine therapy combined with optical penalization.  J Pediatr Ophthalmol Strab. 2005;  42 52-53
• 40 von Noorden G K, Campos E C. Patching regimens.  Ophthalmology. 2004;  111 1063 1064-1066
• 41 Pediatric Eye Disease Investigator Group . A randomized trial of atropine vs. patching for treatment of moderate amblyopia in children.  Arch Ophthalmol. 2002;  120 268-278
• 42 Pediatric Eye Disease Investigator Group . A comparison of atropine and patching treatments for moderate amblyopia by patient age, cause of amblyopia, depth of amblyopia, and other factors.  Ophthalmology. 2003;  110 1632-1637
• 43 Rahi J, Logan S, Timms C, Russell-Eggitt I, Taylor D. Risk, causes, and outcomes of visual impairment after loss of vision in the non-amblyopic eye: a population-based study.  Lancet. 2002;  24 597-602
• 44 Repka M X, Beck R W, Holmes J M, Birch E E, Chandler D L, Cotter S A. et al. . A randomized trial of patching regimens for treatment of moderate amblyopia in children.  Arch Ophthalmol. 2003;  121 603-611
• 45 Repka M X, Wallace D K, Beck R W, Kraker R T, Birch E E, Cotter S A. et al. . Two-year follow-up of a 6-month randomized trial of atropine vs. patching for treatment of moderate amblyopia in children.  Arch Ophthalmol. 2005;  123 149-157
• 46 Repka M X, Cotter S A, Beck R W, Kraker R T, Birch E E, Everett D F. et al. . A randomized trial of atropine regimens for treatment of moderate amblyopia in children.  Ophthalmology. 2004;  111 2076-2085
• 47 Repka M X, Holmes J M, Melia B M, Beck R W, Gearinger M D, Tamkins S M, Wheeler D T. Pediatric Eye Disease Investigator Group . The effect of amblyopia therapy on ocular alignment.  J AAPOS. 2005;  9 542-545
• 48 Rosenbaum A L, Bateman J B, Bremer D L, Liu P Y. Cycloplegic refraction in esotropic children. Cyclopentolate versus atropine.  Ophthalmology. 1981;  88 1031-1034
• 49 Rutstein R P, Fuhr P S. Efficacy and stability of amblyopia therapy.  Optom Vis Sci. 1992;  69 747-754
• 50 Scheiman M M, Hertle R W, Beck R W, Edwards A R, Birch E, Cotter S A. et al. . Randomized trial of treatment of amblyopia in children aged 7 to 17 years.  Arch Ophthalmol. 2005;  123 437-447
• 51 Simonsz H J, Polling J R, Voorn R, van Leeuwen J, Meester H, Romijn C, Dijkstra B G. Electronic monitoring of treatment compliance in patching for amblyopia.  Strabismus. 1999;  7 113-123
• 52 Sjöstrand J, Abrahamsson M. Risk factors in amblyopia.  Eye. 1990;  4(Pt 6) 787-793
• 53 Stewart C E, Moseley M J, Stephens D A, Fielder A R. Treatment dose-response in amblyopia therapy: the Monitored Occlusion Treatment of Amblyopia Study (MOTAS).  Invest Ophthalmol Vis Sci. 2004;  45 3048-3054
• 54 Stewart C E, Moseley M J, Fielder A R, Stephens D A. MOTAS Cooperative . Refractive adaptation in amblyopia: quantification of effect and implications for practice.  Br J Ophthalmol. 2004;  88 1552-1556
• 55 Vereecken E P, Brabant P. Prognosis for vision in amblyopia after the loss of the good eye.  Arch Ophthalmol. 1984;  102 220-224
• 56 Wallace D K. et al. . A randomized trial to evaluate 2 hours of daily patching for strabismic and anisometropic amblyopia in children.  Ophthalmology. 2006;  113 904-912